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Purpose: To develop an in situ gel system comprising liposome-containing paclitaxel (PTX) 
dispersed within the thermoreversible gel (Pluronic® F127 gel) for controlled release and 
improved antitumor drug efficiency.
Methods: The dialysis membrane and membrane-less diffusion method were used to investigate 
the in vitro drug release behavior. Differential scanning calorimetry (DSC) thermal analysis was 
used to investigate the “micellization” and “sol/gel transition” process of in situ gel systems.   
In vitro cytotoxicity and drug uptake in KB cancer cells were determined by MTT, intercellular 
drug concentration, and fluorescence intensity assay.
Results: The in vitro release experiment performed with a dialysis membrane model showed 
that the liposomal gel exhibited the longest drug-release period compared with liposome, gen-
eral gel, and commercial formulation Taxol®. This effect is presumably due to the increased 
viscosity of liposomal gel, which has the effect of creating a drug reservoir. Both drug and gel 
release from the in situ gel system operated under zero-order kinetics and showed a correlation 
of release of PTX with gel, indicating a predominating release mechanism of the erosion type. 
Dispersing liposomes into the gel replaced larger gel itself for achieving the same gel dissolu-
tion rate. Both the critical micelle temperature and the sol/gel temperature, detected by DSC 
thermal analysis, were shifted to lower temperatures by adding liposomes. The extent of the 
shifts depended on the amount of embedded liposomes. MTT assay and drug uptake studies 
showed that the treatment with PTX-loaded liposomal 18% Pluronic F127 yielded cytotoxici-
ties, intercellular fluorescence intensity, and drug concentration in KB cells much higher than 
that of conventional liposome, while blank liposomal 18% Pluronic F127 gel was far less than 
the Cremophor EL® vehicle and empty liposomes.
Conclusions: A thermosensitive hydrogel with embedded liposome is a promising carrier 
for hydrophobic anticancer agents, to be used in parenteral formulations for treating local 
cancers.
Keywords: controlled release, cytotoxicity evaluation, drug uptake
Introduction
Paclitaxel (PTX) is a well known antineoplastic agent which acts through a number of 
mechanisms; that is, as a mitotic inhibitor (microtubule stabilization), an antiangiogenic 
agent, and a radiation sensitizer. It has been clinically used in the treatment of a wide 
variety of cancers, such as ovarian, skin, breast, and lung cancers.1–3 The anticancer 
activity of PTX is dependent both on its concentration and the duration of exposure.4–6 
Although it is widely used in cancer chemotherapy, several problems associated with International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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its clinical use remain unresolved. Its poor aqueous solubil-
ity necessitates intravenous delivery of the drug via lipo-
philic solvents such as the Cremophor/ethanol combination 
(Taxol®). This formulation has limited stability on dilution 
and is associated with significant vehicle-related toxicity in 
the clinical setting.7–9 Like most chemotherapeutic drugs, 
PTX has a narrow therapeutic window and short elimination 
half-life, thus requiring higher doses. However, the toxicity 
of solvent systems (eg, Cremophor EL®/ethanol) limits the 
maximum intravenous dose of PTX that can be safely used. 
New formulations that overcome these problems will have 
clear clinical advantages. In recent years, various groups of 
researchers have investigated the development of novel for-
mulations for PTX, including liposomes,10–15 emulsions,16–19 
cyclodextrins,20–22 microspheres,23,24 nanoparticles,25–31 
and implants.32–35 In   addition, injectable thermoreversible 
hydrogels are also being developed with reasonable success 
for PTX delivery.36–39 The unique advantages of this kind of 
drug delivery system, which include the provision of targeted 
cytotoxicity, and controlled release of a drug without systemic 
toxicities, have made it more and more attractive as a system 
with great potential for treating cancer.
Pluronic® F127 (F127) is one of the most important 
thermoreversible hydrogels, and it is commercially available. 
It is usually regarded as nontoxic and has been applied in 
localized drug delivery such as intramuscular, intraperitoneal, 
and subcutaneous injections.40 A moderately concentrated 
solution of F127 forms a free-flowing solution at or below 
normal ambient temperature and is able to form a gel at 
body temperature, as the micelles form partially ordered 
cubic phases as the micellar cores dehydrate.41 Therefore, 
it has been widely exploited as a topical drug delivery 
carrier of anticancer agents, and for the covering of burn 
wounds. It also has been used in rectal, ophthalmic, paren-
teral, and nasal administrations, as well as in subcutaneous 
administrations.42,43 For localized cancer therapy, intratumoral 
or peritumoreal injection of this gel will lead to the forma-
tion of a ‘depot’ at the site of administration that slowly and 
continuously releases the drug to the tumor and surrounding 
tissue. Using a topical or injectable gel for physical target-
ing has additional advantages over passive or other actively 
targeted therapies in that it can deliver a drug throughout the 
tumor regardless of vascular status, thus providing accurate 
dosing without systemic toxicity.38
Liposomes are widely used in parenteral pharmaceuti-
cal dosage forms because they offer many advantages for 
delivery. In addition to drug targeting, they can increase 
the   stability of various amphipathic molecules, improve the 
solubility of poorly water-soluble drugs, and can substitute 
for common but toxic nonaqueous cosolvents. PTX has 
poor aqueous solubility; however, at low concentrations, 
PTX completely dissolves in poloxamer gel while forming 
a suspension at higher concentrations.44 Dhanikula et al also 
observed that at higher loadings, direct incorporation of 
paclitaxcel in gel leads to its precipitation.45–47 On the other 
hand, we believe that the incorporation of liposomal PTX 
into poloxamer gel should increase drug loading while, in 
all probability, yielding slower, more prolonged drug release 
compared with pure gel. Therefore, a system containing both 
F127 and liposome could be of great interest because they 
pair up the best of two worlds – the thermogelling properties 
of F127 and the carrier ability of the liposome.
In this study, F127 aqueous systems with different amounts 
of liposome were evaluated. In vitro release studies, thermal 
analysis investigation, and cancer cell cytotoxicity and cell 
drug uptake assays were made in order to outline the systems’ 
potential uses as parenteral formulations for localized cancer 
therapy. This work lays the foundation for developing a PTX 
delivery system joining the in situ thermogelling characteristic 
of F127 with the advantages offered by liposomes.
Materials and methods
Materials
PTX (molecular weight 853.4) was obtained gratis from Jiang 
Su AoSaiKang Co, Ltd (Jiangsu, China). F127 was obtained 
gratis from BASF (Hanover, Germany). Soybean phospholip-
ids (lipids containing soya phosphatidylcholile [SPC]) were 
purchased from Shanghai Taiwei Co, Ltd (Shanghai, China). 
Nitro-benzoxadiazol-labeled phosphatidylethanolamine 
(NBD-PE) was purchased from Avanti Polar Lipids (Ala-
baster, AL). All solvents used were of analytical grade and 
were purchased from Sigma-Aldrich (St. Louis, MO). All the 
solutions were prepared using water from a Milli-Q®   Gradient 
filtration system (Millipore, Billerica, MA).
Methods
Preparation of liposome
The solvent dispersion (ether injection) method was adopted 
for liposome preparation. Briefly, lipids containing SPC 
(250 mg) with or without PTX (20 mg) were dissolved in 3 mL 
ether as the organic phase and mixed thoroughly. A needle 
was used to draw up all the organic phase, which was then 
deposited just below the surface of the aqueous phase, a 
20 mL phosphate-buffered saline (PBS) (pH 7.4), as it was 
being stirred rapidly. Stirring continued with a magnetic bar 
at a temperature of 55°C for 20 minutes. The suspension of International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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lipids was then extruded six times through a 0.1 µm pore-size 
polycarbonate membrane (Nuclepore Track-Etch Membrane) 
using a LipexTM Extruder (Northern Lipids Inc., Vancouver, 
BC, Canada) driven by pressurized nitrogen to remove unin-
corporated drug aggregates. Liposomes thus obtained were 
stored at room temperature for further research.
For fluorescence microscopy, 1.0 mol% of NBD-PE 
relative to the total lipids was added to the liposome 
formulations.
Preparation of gel
The “cold” method was adopted for preparation of Pluronic 
gels as described by Soga et al.48 Briefly, F127 (1.8 g) was 
added to 10 mL PBS (pH 7.4) aqueous solution in flat-
bottomed screw-capped glass vials, and gently mixed with 
magnetic stirrers for 24 hours at 4°C until all of the Pluronic 
granules were completely dissolved and a clear solution was 
obtained. Excess PTX powder was added to the clear 18% 
F127 solution prepared above and gently mixed with the 
magnetic stirrers for 24 hours at 25°C. This mixture was 
filtered through a 0.22 µm filter (Millipore) to remove unin-
corporated drug aggregates, and then the obtained gels were 
stored at room temperature for further research.
Preparation of liposomal gel
The required amount of Pluronic granules was added to blank 
liposome or PTX–liposome solution in flat-bottomed screw-
capped glass vials, and gently mixed with magnetic stirrers 
for 24 hours at 4°C until all of the Pluronic granules were 
completely dissolved and a clear solution was obtained. In 
the present experiment, the F127 concentration in F127 gel 
is always expressed as the weight percentage (wt%), unless 
specified otherwise.
In vitro release studies of PTX formulation
In vitro release of PTX using dialysis membrane method
Drug release profiles from liposomal PTX, PTX 18% F127, 
and liposomal–PTX 18% F127 formulation, with equivalent 
PTX drug concentration (300 µg/mL), were evaluated using 
the dialysis membrane method. For comparison, a commercial 
formulation (Taxol) was prepared in our laboratory according 
to a previous report.48 Briefly, 12 mg of PTX was dissolved 
in 1.0 mL ethanol, and to this solution 1.0 mL Cremophor 
EL was added. This mixture was then sonicated for 30 min-
utes. The obtained Taxol formulation (PTX = 6 mg/mL) 
was diluted with Cremophor EL/ethanol (1:1, v:v) solvent 
(Taxol/Cremophor EL–ethanol), or PBS (pH 7.4) solution 
(Taxol/PBS) to make 300 µg/mL of PTX.
An aliquot of each PTX solution (0.5 mL) was placed 
in a pre-swollen dialysis bag with a 12,000–14,000 Da 
molecular weight cutoff (Spectra/Por® 2 dialysis membrane; 
Spectrum Laboratories, Auckland, NZ) and immersed into 
6 mL of release medium, ie, PBS (pH 7.4) containing 0.1% 
(v/v) Tween 80 to maintain sink condition,11 contained in a 
flat-bottomed glass vial (internal diameter about 20 mm), 
and then the vial was shaken in a thermostatic shaker at 
37°C at 40 ± 10 rpm.49 Samples were withdrawn at prede-
termined time intervals over a 24-hour period and refilled 
with the same amount of the fresh medium. Concentration 
of PTX was determined using an ultra performance liquid 
chromatography (UPLC) system after appropriate dilution 
with acetonitrile.
The UPLC system was equipped with a Waters 2487 
Dual l Absorbance Detector, 717 plus Autosampler and 515 
dual pumps. A reverse phase ACQUITY UPLC® BEH Shield 
C18 column (2.1 mm × 100 mm, 1.7 µm; Waters, Wexford, 
Ireland) was used at room temperature, and the detector 
wavelength was set at 227 nm. A mixture of acetonitrile: 
water (50:50, v/v) was used as the mobile phase at a flow 
rate of 1.0 mL/min.
In vitro release of PTX using a membrane-less  
diffusion method
A membrane-less diffusion system was used for studying 
drug release from the PTX 18% F127 gels or liposomal–PTX 
18% F127 gels, and the poloxamer dissolution from Pluronic 
gels or liposomal Pluronic gels. A volume of 1 mL of the ther-
moreversible solution at room temperature was put into the 
bottom of a pre-weighed empty glass tube (12 mm × 75 mm) 
and then placed in a water bath (37°C) until a clear gel 
formed; the initial weight of each tube plus the gel was 
recorded. A volume of 2 mL of the release medium (PBS, pH 
7.4, containing 0.1% [v/v] Tween 80) pre-equilibrated at 37°C 
was carefully layered over the surface of the gel. The tube was 
then shaken in a thermostatic shaker at 37°C at 40 ± 10 rpm. 
At predetermined timepoints, the release medium was totally 
replaced by fresh medium, and the weight of the tube plus 
the gel was recorded to calculate the weight of gel dissolved. 
The total PTX released into the medium was determined after 
appropriate dilution with acetonitrile and submitted to the 
UPLC system. The proportions of free PTX and PTX still 
encapsulated in the liposome or micelle released from the 
gel was determined after   ultracentrifugation (10000 g, 15°C, 
30 minutes) in centrifugal filter tubes (MWCO 10ku), and 
filtrate containing only free PTX was submitted to the UPLC 
system. The difference between total PTX released into the International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
154
Nie et al
medium and free PTX allowed us to calculate the amount 
of PTX released from the gel but still encapsulated in the 
liposome or micelle.
Drug release kinetics study
To investigate the kinetics of drug release from gels in 
  membrane-less diffusion systems, several mathematical mod-
els describing the kinetic behavior of drug release from gels 
were assessed.50–52 The drug release kinetics were determined 
by the best fit of the experimental data (amount of released 
drug versus time) to the kinetic models as described below:
  Higuchi release model: Mt/M∞ = Kht½,  (1)
where Mt/M∞ is the fraction of drug released at each timepoint 
(t), and Kh represents the Higuchi release kinetic constant.
  Zero-order release model: Mt/M∞ = K0t,  (2)
where Mt/M∞ is the fraction of drug released at each time-
point (t), and K0 represents the zero-order release kinetic 
constant.
  First-order release model: Mt/M∞ = 1 - e-K1t,  (3)
where Mt/M∞ is the fraction of drug released at each time-
point (t), and K1 represents the first-order release kinetic 
constant.
Drug release mechanism study
The drug release mechanism was studied using the semiem-
pirical Power law model and Ritger–Peppas model. The Power 
law exponential expression has been extensively used by 
various pharmaceutical systems as follows:53–56
 M t/M∞ = Ktn,  (4)
where Mt/M∞ is the fraction of drug released at each time-
point (t), K is a kinetic constant incorporating structural and 
geometric characteristics of the device, and n is the release 
exponent, indicative of the mechanism of drug release. As 
the release mechanism from polymeric systems is complex, 
this model is used when the exact mechanism is unknown or 
when more than one release mechanism is involved in drug 
release. Equation (4) has two distinct meanings, one in the 
special case of n = 0.45 (indicating diffusion-controlled drug 
release, also called Fickian diffusion kinetics), and a second 
in the special case of n = 0.89 (indicating erosion-controlled 
drug release, also called case II transport kinetics) for a 
cylindrical polymeric matrix. Values of n between 0.45 and 
0.89 can be regarded as an indicator for the superposition of 
both phenomena (anomalous transport). When determining 
the n exponent, only the portions of the release curve where 
Mt/M∞ , 60% were used.
Best fit of all datapoints (up to 100% of release curves) 
was achieved by another interesting Ritger–Peppas model:
 M t/M∞ = Katm + Kbt2m,  (5)
where Mt/M∞ is the fraction of drug released at each time-
point (t), and Ka, Kb, and m are constants. This equation was 
previously proposed to describe the release of molecules 
from polymeric matrices when diffusion is not the only 
determining factor for release, but other mechanisms, such as 
polymer relaxation parameters, are also important. The first 
term on the right-hand side represents the Fickian diffusional 
contribution, whereas the second term represents the case II 
relaxational contribution. The m value of 0.45 was taken in 
our study based on the aspect ratio of the matrices. The ratio 
of relaxational to Fickian contributions is given by: 
  R/F = Kbtm/Ka  (6)
The effect of liposome on F127 system
The sol-gelation temperature of the F127 gel (16%–27%) in 
PBS (pH 7.4) with and without liposome was roughly deter-
mined using the tube inversion method described previously. 
Briefly, each formulation was heated slowly from 10°C to 
50°C at a heating rate of 1°C/min, until the solution totally 
lost fluidity; the temperature obtained was recorded as the 
gelation temperature.
Differential scanning calorimetry (DSC) was used to 
investigate the interaction of liposome and F127, and also 
used to analyze the self-assembling and thermogelation 
properties of F127 systems more accurately. The aqueous 
solutions of F127 in the absence and presence of liposome 
were analyzed. Samples (approximately 50 mg) were loaded 
in the calorimetric cells at 0°C, heated from -10°C to 60°C 
at 5°C/min, then cooled from 60°C to -10°C at 5°C/min 
by Jade DSC (PerkinElmer, Waltham, MA). A delay of 
5 minutes was utilized between sequential scans to allow 
thermal equilibration. Data analysis was performed with the 
software preinstalled in the instrument (Pyris Data Analysis; 
PerkinElmer).
cell culture
Human oral cancer KB cell line was obtained from   American 
Type Culture Collection and grown in RPMI medium 
1640 (Gibco/Invitrogen, Carlsbad, CA) supplemented with 
10% fetal bovine serum (FBS) (Gibco/Invitrogen) and 1% 
penicillin/streptomycin (Gibco/Invitrogen) in a humidified International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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incubator under the conditions of 37°C, 5% CO2, and 90% 
relative humidity. After reaching confluence, the cells were 
prepared by washing in PBS and detached from the dish 
with trypsin-EDTA (Gibco/Invitrogen). The cells were then 
transferred to a centrifuge tube and centrifuged at a speed of 
1000 rpm for 5 minutes, and the cells were resuspended to 
obtain a concentration of 5 × 104 cells/mL.
cell cytotoxicity study
KB cells were seeded in a 96-well plate at a density of 
5 × 103 cells per well, 24 hours before the in vitro cytotoxicity 
studies started. PTX formulation loaded with Taxol, liposome, 
or liposomal 18% F127 gel was prepared with PBS (pH 7.4) 
as described above (with equivalent PTX concentration of 
300 µg/mL. Control formulations without PTX were also 
prepared using the same procedure. The three stock solutions 
were filtered through sterile 0.22 µm Millipore paper, and then 
further diluted with sterile PBS (pH 7.4) stepwisely to make 
PTX concentrations in the range of 0.0003–300 µg/mL. To 
evaluate their cytotoxic effects, 100 µL of the PTX formu-
lations and 100 µL of the culture medium (RPMI Medium 
1640 + 10% FBS) were added to the cells. As the reference, 
100 µL of the culture medium was added to the cells as well 
as 100 µL of PBS (pH 7.4). The cells were incubated for 24, 
48, and 72 hours at 37°C in a humidified atmosphere with 
5% CO2. After incubation, the number of viable cells was 
determined by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium bromide (MTT)   colorimetric assay.
A volume of 20 µL of MTT solution (5 mg/mL) was 
added to each well. The plates were incubated for an addi-
tional 4 hours, and then the medium was discarded. A vol-
ume of 150 µL of DMSO (dimethyl sulfoxide) was added to 
each well, and the solution was vigorously mixed to dissolve 
the reacted dye. The absorbance (A) of each well was read on 
a microplate reader (BIO-RAD Benchmark Plus/microplate 
spectrophotometer, UK) at a test wavelength of 570 nm and 
reference wavelength of 650 nm. The c sample was tested 
in triplicate, and six wells with only culture medium served 
as blanks; the relative cell viability (%) was calculated as 
(Aof treated cells/Aof untreated cells) × 100%.
Measurement of intracellular drug concentration
KB cells were suspended in the culture medium (1 mL) at a 
density of 1 × 106 cells/well in 24-well flat-bottom tissue cul-
ture plates. After 24 hours, the medium was replaced with 1 mL 
of FBS-free culture media containing a formulation loaded 
with 500 ng/mL of PTX. Each cell in triplicate was incubated 
for 1, 2, 4, and 6 hours (37°C). The cells in each well were 
washed with cold PBS twice to remove nonuptaken drug, and 
100 µL trypsin-EDTA solution (0.25%) was added. A volume 
of 0.5 mL acetonitrile was added to destroy the cell and pre-
cipitate the protein, and then after centrifugation at 10,000 rpm 
for 10 minutes, 2 µL of the supernatant was used for UPLC 
detection to obtain the intracellular drug concentration.
cellular uptake and distribution  
of fluorescent blank liposome
For qualitative study, KB cells were seeded in a 96-well 
plate at a density of 5 × 104 cells per well in 100 µL of 
the culture medium and cultured for 24 hours before the 
experiment. For studying liposome uptake and distribution 
by fluorescent microscopy, 20 µL of NBD-labeled liposome 
or NBD-labeled liposomal 18% F127 formulation without 
PTX (liposome contained 1.0 mol% of NBD-PE relative to 
the phospholipids) and 100 µL culture medium was added to 
the cells. As a reference, 100 µL culture medium was added 
as well as 20 µL PBS (pH 7.4) and 20 µL PBS (pH 7.4). After 
1-hour and 4-hour incubation, cells were washed twice with 
cold PBS (pH 7.4) and directly observed under a fluorescence 
microscope (Inverted Microscope Axiovert 200; Carl Zeiss, 
Wetzlar, Germany).
For quantitative study, 20 µL trypsin-EDTA solution 
(0.25%) was added to detach the cells after washing the 
cells with cold PBS. The cells were then harvested by adding 
200 µL acetonitrile three times to obtain the cell lysate and the 
dissolved NBD-PE. Finally, the cell lysate was centrifuged at 
10,000 rpm for 10 minutes, and the supernatant was used for 
fluorescence assay with a fluorometer (LS 55, Luminescence 
Spectrometer; PerkinElmer) (excitation, 460 nm; emission, 
534 nm). The fluorescence intensity of cell lysate was nor-
malized to that of the reference solution.
statistical analysis
Data were expressed as the means of three separate experi-
ments, and were compared by analysis of variance (ANOVA). 
A P-value , 0.05 (or ,0.01) was considered statistically 
significant in all cases. All data analysis was performed with 
Microsoft Excel (Microsoft Corp, Redmond, WA).
Results and discussion
comparison of the effect of different 
drug-loaded formulations on PTX release 
using dialysis membrane method
The drug-release behaviors of five PTX formulations 
were measured in vitro by the dialysis membrane method 
(Figure 1). Taxol solution showed the fastest release rate. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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PTX formulations, especially the Taxol diluted with PBS, 
simulating clinical treatment form, exhibited a higher 
release rate than that diluted with Cremophor EL/ethanol 
(1:1, v:v) solvent. This is due to the lower viscosity of PBS 
solvent compared with Cremophor EL/ethanol (1:1, v:v) 
mixture solvent. A marked reduction of drug release was 
observed when drug was incorporated into liposomes. The 
release of PTX was rapid and almost complete from the 
Taxol formulation within 12 hours, while the incorporation 
of drug into liposome significantly retarded drug release to 
only 50% released at 12 hours, suggesting that most of the 
drug remained incorporated in liposomes under the study 
conditions. The maintenance of the sink condition in the in 
vitro drug release media signifies that the outer environment 
of the dialysis membrane has a strong solubilization capac-
ity for the insoluble drug; thus, the gradual release of drug 
from the liposomes depends on the incorporating efficiency, 
and its diffusion to the external medium depends on the 
concentration gradient. Our results agree with the general 
conclusion that liposomal entrapment of drugs sustains their 
release. Moreover, further reduction in drug release was 
observed from drug-loaded gels which could be attributed 
to the much higher viscosity of gels compared to the PTX 
solutions. The latter represented a less permeable matrix with 
lower drug release; however, no significant difference was 
observed between liposomal-PTX 18% F127 gel and PTX 
18% F127 gel under the conditions studied.
comparison of PTX release from  
drug-loaded F127 gels performed  
by membrane-less method
When the PTX-loaded gels were separated from the release 
medium by a dialysis membrane, the dissolution of F127 gel 
was almost prevented, and diffusion dominated the drug 
release mechanism. In contrast, the membrane-less model, 
also used in our study, allowed the release medium solution 
to directly contact the gel surface and thereby dissolve the gel. 
As shown in Figure 2, the dispersion of liposomes within the 
18% F127 gel led to a much slower drug release than the 
simple micelle gel formulation without liposomes at each 
timepoint. The difference is more distinct compared with 
the dialysis membrane method. The form of PTX released 
from 18% F127 gels (free PTX or PTX still encapsulated in 
liposomes or micelles) was quantified. The results indicated 
that total PTX released was almost encapsulated in lipo-
somes or micelles during the whole periods of release time 
from both gel formulations, which was due to the high PTX 
entrapment efficiency (∼100%) of PTX liposomes or micelles 
determined by substracting free drug fraction, as described 
in the section ‘In vitro release of PTX using membrane-less 
diffusion method’ above.
One reason for the lower release of liposomal PTX 
from 18% F127 could be the ‘reservoir effect’; that is, the 
liposome carrier acts as a reservoir within the gel, lowering 
the diffusion rate from the inner gel to the outer medium. 
This phenomenon is also present in dialysis membrane 
experiments. However, besides the diffusion mechanism, 
there could be another important mechanism contribut-
ing to the drug-release behavior because the gradually 
decreasing volume of gel could be clearly observed in the 
membrane-less dissolution experiments, and most of the 
gel formulations had completely disappeared by the final 
timepoint.
The best fit between dissolution profiles and kinetic mod-
els was obtained with the Power law equation (R2 . 0.997 
for both drug-loaded gels), and values of n higher than 0.89 
(n = 0.951 for the liposomal PTX gel, n = 0.974 for the PTX 
gel) indicated that gel erosion was the predominant release 
mechanism (Table 1). In addition, K values calculated for 
liposomal PTX gel are lower compared with the equivalent 
values for PTX gels, indicating a lower drug release rate 
for liposomal gels; this fact may be linked to the reservoir 
effect and gel dissolution difference. On the other hand, in 
vitro drug release followed the zero-order release model 
better than the Higuchi model and the first-order model 
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Figure 1 In vitro drug release kinetics from Taxol® ( ), Taxol diluted with PBs   
( ), liposomal-PTX solution ( ), liposomal-PTX 18% F127 gel ( ), and PTX 
18% F127 gel ( ), using the dialysis-membrane model at 37°c. Data are expressed 
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for the highest R2 values (R2 . 0.997 for both drug-loaded 
gels), showing that release of drug from gels does not 
properly follow Fickian diffusion kinetics, but instead fol-
lows matrix erosion kinetics. The difference in the kinetic 
constant K0, between liposomal PTX gel and PTX gel also 
confirmed that the release of drug is lower from a liposomal 
gel system (K0 = 0.073) than from a pure micellar gel system 
(K0 = 0.124).
Since only the first four or six datapoints (for the first 
60% of release curves) could be used when analyzing release 
results with the Power law equation, the best correlations were 
further obtained when applying the two-parameter   equation 
(Equation (5)) (R2 . 0.99 for both drug-loaded gels) for 
the 100% of release curves. With this analysis, the kinetic 
constant Kb (relaxational contribution) was much higher than 
Ka (diffusion contribution) in both formulations (Kb = 0.0914 
and Ka = 0.0073 for liposomal-PTX 18% F127 gel compared 
with Kb = 0.1118 and Ka = 0.0643 for PTX 18% F127 gel). 
This proves that the most significant processes for PTX 
release are erosion-type processes (Table 1).
correlation between gel  
dissolution and drug release
To investigate whether the difference observed in PTX release 
between the liposome-in-gel system and the micelle-in-gel 
system is due to the extreme difference in the gel dissolution 
rate or erosion rate in each case, extra experiments were per-
formed, in which the dissolution behavior of these two drug-
loaded gel formulations was investigated by weighing them 
at the same timepoints (Figure 3). The remaining weight% 
of gels also followed zero-order kinetics (R2 . 0.99), and 
the good linear correlation between the percentage of PTX 
released and the percentage of gel dissolved further indicated 
a distinct polymer dissolution-controlled release mechanism 
(R2 . 0.99) (Figure 4). Similar zero-order release kinetics 
could be found in previous reports for recombinant hirudin,57 
interleukin-2,58 insulin,43 and ceftiofur.59 However, first-order 
kinetics and Higuchi kinetics have also been reported.60–62 
This discrepancy might be due to differences in experimental 
conditions, or in drug and gel properties. In our study, PTX 
was very poorly water soluble, which differs from those water 
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Figure 2 In vitro drug release kinetics from F127 gels as a function of time (hours), using the membrane-less model at 37°c. Data are expressed as mean ± standard 
deviation (n = 3). A) Liposomal-PTX 18% F127 gel:   for total drug,   for free drug,   for liposomal drug. B) PTX 18% F127 gel:   for total drug,   for free drug, 
 for micellar drug. 
Abbreviations: F127, Pluronic® F127; PTX, paclitaxel.
Table 1 Data from regression fitting between dissolution profiles (obtained from liposomal-PTX 18% F127 gel and PTX 18% F127 gel) 
and several kinetic models (Higuchi, zero-order, and first-order) and the Power law and Ritger-Peppas model (release mechanism)
Kinetic models Liposomal-PTX 18% F127 PTX 18% F127
Fitting equation R2 Fitting equation R2
higuchi model Mt/M∞ = 0.222t1/2 0.862 Mt/M∞ = 0.293t1/2 0.871
Zero-order model Mt/M∞ = 0.073t 0.991 Mt/M∞ = 0.1243t 0.979
First-order model Mt/M∞ = 1 - e-0.142t 0.887 Mt/M∞ = 1 - e-0.283t 0.858
Power law model Mt/M∞ = 0.08t0.951 0.993 Mt/M∞ = 0.13t0.974 0.975
ritger-Peppas model Mt/M∞ = 0.0073t0.45 + 0.0914t0.9 0.998 Mt/M∞ = 0.0643t0.45 + 0.1118t0.9 0.968
Note: Mt/M∞ is the fraction of drug released at each timepoint (t).
Abbreviations: F127, Pluronic® F127; PTX, paclitaxel.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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soluble compounds previously reported. Thus, the molecular 
diffusion from the inner gel to the outside medium would be 
limited, as demonstrated in the dialysis membrane method, 
especially in PBS (pH 7.4) without Tween-80 solution, like 
the circumstance of gel inner-side. This implies that the 
release rates of lipophilic drugs are more dependent on the 
polymeric matrix dissolution rate than the diffusion rate.
In fact, gel relaxation or erosion contributes almost 90% 
of drug release from liposome-in-gel systems in the whole 
dissolution process, whereas these processes contribute 
only 60%–80% of drug release from micelle-in-gel systems 
(Figure 5). This phenomenon was demonstrated more clearly 
with liposomal gels than pure gels, because the ratio of 
relaxational over Fickian contributions (R/F value) is much 
higher for the liposome-in-gel system compared with the 
micelle-in-gel system at every timepoint (Figure 6). This 
further proves that polymer dissolution is an important fac-
tor determining release of poorly water-soluble drugs from 
F127 gels. The liposome dispersed in the F127 gel could 
significantly reduce the erosion rate of formulation. So, it is 
important that the dissolution rate of the gel would be signifi-
cantly affected by the formulation composition, especially 
when liposome is involved in the poloxamer gel.
effect of different concentrations 
of poloxamer or liposome on gel 
dissolution
To investigate whether gel dissolution could be modified by 
adding different amounts of liposomes, the dissolution rate 
was evaluated in the case of drug-free liposomal F127 gel 
with low (0.21%, w/v), middle (0.42%, w/v), and high 
(1.25%, w/v) lipid content at the same polymer concentration 
of 18%. For comparison, the dissolution rate of drug-free 
F127 gels containing no liposome (at polymer concentrations 
of 18%, 21%, 24%, and 27%) were also investigated. It was 
seen that the rate of gel dissolution significantly decreased 
with the increase of F127 concentration (P , 0.05) and 
also with increase of lipid content in the gel (P , 0.05), 
and the addition of PTX did not significantly change the 
gel dissolution rate when compared with drug-loaded gel 
(P . 0.05) (Figure 7). On the other hand, the dissolution 
profile of liposomal 18% F127 gel with low, medium, and 
high lipid content of liposome seemed practically similar to 
pure F127 gel with polymer concentrations of 21%, 24%, 
and 27%, respectively (Figure 7). As shown in Table 2, the 
zero-order kinetic model fitted well with the gel dissolution 
profiles in Figure 7 (R2 . 0.99 for all the gel formulations), 
0246
Time (hours)
D
r
u
g
 
r
e
l
e
a
s
e
d
81 01 21 4
0%
20%
40%
60%
80%
100%
120%
G
e
l
 
r
e
m
a
i
n
i
n
g
 
w
e
i
g
h
t
0%
20%
40%
60%
80%
100%
120%
Figure 3 In vitro drug release (%) from F127 gels (  for liposomal-PTX 18% F127 
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mean ± standard deviation (n = 3). 
Abbreviations: F127, Pluronic® F127; PTX, paclitaxel.
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and K0 values (release kinetic constant) for low (0.099), 
middle (0.073), and high (0.054) lipid content of liposomal 
18% F127 gels were also close to that for pure 21% (0.097), 
24% (0.076), and 27% F127 (0.058) gels, respectively. This 
indicates that incorporation of F127 with 0.21%–1.25% SPC 
as liposomes may achieve the same gel dissolution rate as 
F127 with 3%–9% higher polymer concentration. This is 
significant, as the toxicity of poloxamer formulation is related 
to the copolymer concentration. Thus, instead of increasing 
copolymer concentration, simply dispersing liposome in gels 
with different concentrations according to therapeutic needs 
can easily and flexibly adjust in vitro dissolution behavior. 
In this case, obtaining a more controlled or sustained drug 
release behavior for meeting a more reasonable need of 
clinical treatment only depends on decreasing the amount 
of copolymer.
In our study, an easier and safer way to reduce the drug 
release rate was found to meet long-term treatment needs for 
certain diseases, such as localized injection of certain antitu-
mor drugs in cancer therapy. The adding of liposomal drug 
to thermoreversible hydrogel can not only avoid the potential 
toxicity of greater amounts of copolymer (usually reported for 
above 20% F127 gel formulation),47,57,60,63,64 but also provide 
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Figure 5 Fickian diffusional contribution (%) (  for liposomal-PTX 18% F127 gel, 
 for PTX 18% F127 gel) and case II relaxational contribution (%) (  for liposomal-
PTX 18% F127 gel,   for PTX 18% F127 gel) to the drug accumulative release from 
F127 gel as a function of time (hours). The data are re-plotted according to ritger-
Peppas equation. 
Abbreviations: F127, Pluronic® F127; PTX, paclitaxel.
R
/
F
 
v
a
l
u
e
0
10
20
30
40
50
0246
Time (hours)
81 01 4 12
Figure 6 R/F value profile (  for liposomal-PTX 18% F127 gel,   for PTX 18% 
F127 gel) as a function of time (hours). The data are re-plotted according to ritger-
Peppas equation. 
Abbreviations: F127, Pluronic® F127; PTX, paclitaxel.
Table 2 Data from regression fitting between gel dissolution 
profiles (obtained from F127 gels and liposome F127 gels) and 
zero-order model
Formulation Zero-order model  
fitting equation
R2
18% F127 Mt/M∞ = 0.1244t–0.0051 0.989
21% F127 Mt/M∞ = 0.097t–0.0173 0.994
24% F127 Mt/M∞ = 0.0761t–0.0107 0.987
27% F127 Mt/M∞ = 0.058t–0.0254 0.998
Low concentration  
liposomal 18% F127
Mt/M∞ = 0.0985t–0.0127 0.999
Medium concentration  
liposomal 18% F127
Mt/M∞ = 0.0732t–0.0084 0.996
high concentration  
liposomal 18% F127
Mt/M∞ = 0.054t–0.0394 0.996
Note: Mt/M∞ is the fraction of drug released at each timepoint (t).
Abbreviation: F127, Pluronic® F127.
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Figure 7 In vitro gel dissolution (dissolved wt%) of F127 gel without drug (  for 
18% F127 gel,   for 21% F127 gel,   for 24% F127 gel,   for 27% F127 gel,   
 for liposome (with low lipid content) 18% F127 gel,   for liposome (with 
medium lipid content) 18% F127 gel,   for liposome (with high lipid content) 
18% F127 gel), using the membrane-less model at 37°c. Data are expressed as 
mean ± standard deviation (n = 3).
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higher drug loading (about 1020 µg/mL, determined in our 
experiment) than that possible with copolymer micelle gel 
alone (about 430 µg/mL, determined in our experiment). 
Potentially, the drug dose could be flexibly adjusted accord-
ing to therapeutic needs for different individual patients and 
different disease states, simply by dispersing different lipo-
some concentrations in gels.
Moreover, liposomal PTX incorporated into an 18% 
F127 hydrogel vehicle could improve the stability of PTX 
liposome. The poor physical stability of PTX liposomes was 
apparent after 7 days from the date of preparation at room 
temperature by our visual observation, and was generally due 
to sedimentation and aggregation during storage. However, 
in the case of liposomal 18% F127 formulations, no per-
ceptible change in appearance by microscope observation 
was observed when stored at room temperature for 30 days; 
meanwhile no significant changes were found in drug entrap-
ment efficiency and drug content value (data not shown). This 
could be due to a higher viscosity of drug delivery system 
produced by adding F127, which contributes to favorable 
dispersion of liposomes.
Thermal analysis of thermo-sensitive 
F127 system
The inverted tube method showed that F127 PBS (pH 7.4) 
solution with F127 concentration equal to or higher than 18% 
exhibited reversal thermal gelation, transforming from liquid 
into a semisolid gel in 1–2 minutes at the characteristic sol-gel 
transition temperatures which were 29.2°C, 26.4°C, 23.1°C, 
and 20.9°C for 18%, 21%, 24%, and 27% F127 solutions 
without drug, respectively. Increasing the F127 concentration 
could decrease the sol-gel transforming temperature, which 
agreed with previous reports,63,65,66 although the data were not 
identical since a different solvent was used and the experiment 
was performed under different conditions. Moreover, the gela-
tion temperatures of 18% F127 containing low (0.21%, w/v), 
medium (0.42%, w/v), and high (1.25%, w/v) lipid concen-
trations of blank liposomes was found at 27.4°C, 25.8°C, and 
23.1°C, respectively. In many published studies, the effect of 
smaller solutes, salts, cosolvents, or cell culture on the phase 
transform behavior of F127 has been well discussed,41,61,63,67–69 
but the influence of liposomes on the self-assembling and 
thermogelation property of the F127 system has not been 
examined. Therefore, a more easy and sensitive method 
(DSC thermal analysis) was considered for our study in order 
to get more useful information about both micellization and 
  sol-gelation transition processes that are always accompanied 
by the thermoreversible behavior of F127.
It is well known that when F127 is put in water above a 
critical concentration, its structure changes from individual 
block copolymers (unimers) to self-assembling micelles. This 
process, involving aggregation, is defined as   “micellization”. 
At the same time, block copolymers at a given concentration 
are also characterized by a specific temperature at which they 
form micelles (critical micelle temperature, CMT). At   elevated 
temperatures, these systems show phase transformation due 
to the complete dehydration of both PO (propylene oxide) 
and EO (ethylene oxide) blocks.70,71 Thus the systems are, in 
general, liquids at low temperature but give rise to a strong 
gel at a given higher temperature. This process involving 
phase transformation is defined as “sol-gelation transition”. 
The DSC technique was performed to outline the variation 
in the CMT and in the sol-gel transition temperature (SGT) 
of the systems containing different amounts of F127 and 
different amounts of liposomes. In order to better illustrate 
the sol-gel transition, the derivative heat flow (mW/min) is 
plotted against temperature (°C) in Figure 8.
Under the experimental conditions of this study, there was 
a significant endothermic peak with increase in temperature 
for F127 gel samples, representing the CMT of F127 (cause 
of micellization), which could not be found in corresponding 
liposome solution samples in the absence of F127. In addition, 
a small shoulder peak representing SGT was found at a higher 
temperature, which appeared at the right-hand end of the CMT 
peak, corresponding to micelle rearrangement – a cause of 
thermogelation and consistent with previous reports.41,57,71 
However, thermogelation is only accompanied by a small 
enthalpy value; thus, it appears that DSC is less sensitive to 
the occurrence of the sol-gel transition, but more sensitive to 
the onset of rapid micelle formation.
As can be seen in Figure 8A, the CMT peak was shifted 
to a lower temperature with increasing F127 concentration 
for the samples without liposome, but the DSC curve pat-
tern did not change. This result is in agreement with previ-
ously reported data.57,64,71 The SGT as measured by DSC 
agreed with those measured with the inverted tube method. 
Figure 8A also shows an endothermic peak obtained for the 
pure 16% F127 solution. Although at this concentration the 
solution is known to be above the critical micellar concentra-
tion, it was not observed to undergo gelation, behaving as 
a liquid in the temperature range of 0°C–50°C, confirmed 
visually by the inverted tube method. Also, as can be seen 
in Figure 8A, no sol/gel transient weak endothermic peak 
was observed.
The phase behavior of this block copolymer is strongly 
affected by liposomes even when thermoreversibility International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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is maintained. Both micellization and the micelle 
  rearrangement phenomena are shifted to lower temperatures 
upon the addition of liposomes (Figure 8B). It is clear that 
the presence of liposomes with low lipid content allowed 
18% F127 solutions to form thermoreversible gels similar 
to those of pure 21% F127 solution. Likewise, the 18% 
F127 solution with medium lipid content behaved similarly 
to those of pure 24% F127 solution, and 18% F127 solu-
tion with high lipid content was similar to those of the 
pure 27% F127 solution. The possible explanation for this 
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Figure 8 comparison of the micellization and gelation processes of A) pure F127 formulations (16, 18, 21, 24, and 27 wt%) and B) 18% F127 gel containing pure liposome 
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of 5°C/min. For better illustration of the sol-gel transition, the derivative heat flow was plotted against temperature. 
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phenomena is that some of the water molecules would have 
been taken into the hydrophilic inner core of the liposome 
bilayer structure, so the presence of liposomes probably 
caused dehydration of the micelles’ cores, which has been 
suggested as one of the major causes of gelation in these 
systems.41,66 The more liposome present in the F127 solu-
tion, the more water molecules would be located within the 
inner core of the liposomes, and consequently the greater 
the extent of dehydration.
This observation immediately highlights the benefits of 
using drug-loaded liposome carrier in F127 formulations. 
Localized cancer therapy is an important and promising 
application of F127 formulations,36,72–74 and our results indi-
cate that the mere presence of such liposome drug carrier 
could result in a 3–9-wt% decrease in the concentration of 
F127 required for a gel-based delivery formulation, while 
maintaining desirable themoreversibility and gel dissolu-
tion capabilities. We have proven this to be true in in vitro 
gel dissolution experiments. The benefits of such a system 
are many, including lower toxicity concerns regarding the 
copolymer, reduced costs for formulation production, and 
better control over the drug release rate.
cell cytotoxicity study
Figure 9 shows the in vitro viability of KB cancer cells 
after 24, 48, and 72 hours treatment with PTX formulated 
in liposome, liposomal 18% F127, and its current clinical 
dosage form Taxol at the same drug concentration range 
(0.0003–300 µg/mL). From Figure 9, a few general conclu-
sions can be immediately made. The Taxol vehicle showed 
greater cytotoxicity than any other blank formulation, espe-
cially at higher concentrations (300 and 150 µg/mL). The 
cellular viability of the Taxol vehicle was nearly 0%, while 
others were close to 20% (P , 0.01). Therefore, it could 
be expected that in vivo liposome and liposomal F127 gels 
would be far less toxic than the Taxol vehicle; if so, then 
the administration of PTX-loaded liposome and liposomal 
F127 gels at higher drug doses than PTX formulated in the 
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Figure 10 Intracellular PTX concentration against incubation time after the KB 
cells were incubated with the drug in different formulations (  for Taxol,   
for liposome,   for liposomal  18% F127 gel) at 37°c. Data are expressed as 
mean ± standard deviation (n = 3).
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Figure 11 Fluorescence microscopic evaluation of NBD-labeled liposome and liposomal 18% F127 in KB cells after 1 and 4 hours treatment at 37°c. Left panels indicate 
cells visualized in the fluorescence mode; right panels indicate the same fields in the phase-contrast mode. A) Treated with no formulation. B) Treated with NBD-labeled 
liposome. C) Treated with NBD-labeled liposomal 18% F127 gel. 
Abbreviations: F127, Pluronic® F127; NBD, nitro-benzoxadiazol.
Taxol vehicle would be possible. Secondly, in most cases, 
the liposomal-F127 gel demonstrated cytotoxicity greater 
than that of liposome with similar drug loading during the 
entire period. For example, after 24, 48, and 72 hours treat-
ment, KB cell viability was decreased to 79.4%, 59.7%, and 
22.0% by drug, and to 43.5%, 30.7%, and 11.6% by lipo-
somal drug-F127 at 0.3 µg/mL, respectively (P , 0.01). 
Thus, therapeutic advantages might be provided after 
incorporating liposomal PTX into F127 gels. Cytotoxic 
activity was comparable in Taxol and liposomal drug-F127 
formulation. Therefore, PTX remains biologically active as 
an anticancer agent even after incorporation into liposomal 
F127 gels. However, at higher drug concentrations, the 
cytotoxicity of Taxol was stronger than that of liposomes, 
which was apparently due to the Cremophor EL vehicle 
rather than PTX. In contrast, for drug-loaded liposome or 
liposomal F127 gel, the cytotoxicity is largely from the 
toxicity of the drug itself. Besides, the safety of blank lipo-
somal F127 gel was higher than pure liposome, which was 
probably due to the capacity of increasing the cell viability 
of F127 alone below and at the CMC; nevertheless, cell 
viability declined steadily above the CMC.75
cellular uptake study
To clarify the relationship between cytotoxicity and 
drug concentration in the cells, the cellular uptake of 
drug was measured after incubating cells with drug-
loaded   formulation. As shown in Figure 10, the highest 
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and then decreased in most cases. The reduction of 
drug   concentration might be caused by cellular drug 
metabolisms. A slightly lower PTX uptake of cells from 
the liposomes than that from Taxol appeared at 2 and 
4 hours, which might be due to the time delay caused by 
endocytosis of transmembrane transport and sustained 
drug release from the liposomes caused by the “reservoir 
effect”. It is interesting to note that for the liposomal–
F127 formulation, a significantly higher intracellular 
drug concentration was found than that for the liposome 
alone, when the cells were incubated for 2, 4, and 6 hours 
(P , 0.01). These results provide a good explanation for 
the stronger cytotoxicity of drug-loaded liposomal–F127 
than that of drug-loaded liposomes alone observed in cell 
variability assay. Moreover, the cell uptake and distribu-
tion of fluorescent (NBD-PE)-labeled blank liposome in 
KB cells was observed by a fluorescence microscope for 
these two formulations after 1 hour and 4 hours incuba-
tion (Figure 11), while the fluorescence uptake into the 
intracellular matrix was quantitatively estimated by a 
fluorometer after 4 hours incubation. From the images of 
cells, it could be seen that the KB cells with no treatment 
of formulation (Figure 11A) showed a weak undetectable 
green fluorescence. In the case of cells exposed to lipo-
some formulations, the intact liposome was found within 
the cellular components, and at the same time, some dif-
fused fluorescence was clearly observed in the entire intra-
cellular matrix due to the liposome degradation caused 
by the enzymes or   environmental factors in cells during 
the incubation period, resulting in the loss of   structural 
integrity and release of the fluorescent lipid molecule 
into the cytosol (Figures 11B and 11C).   However, a more 
significant finding was that a notably higher fluorescence 
intensity was detected for liposomal–F127 formulation 
than pure liposome (P , 0.01)   (Figure 12). So far, no 
similar experimental results related to this phenomenon 
have been reported. For the moment, it is not clear what 
mechanism of the liposomes' uptake of cells may be 
enhanced by suspending in F127 gel. We speculate that it 
is probably related to surface activation to the cell mem-
brane by an amphiphilic surfactant of F127. Therefore, 
further exploration needs to be carried out to reveal the 
nature of this phenomenon.
Conclusion
According to the results of this study, a thermoreversible 
hydrogel based on F127 containing liposomal PTX can be 
utilized for controlled drug delivery and enhanced drug 
uptake in cancer cells. Firstly, the desired drug release rate 
from this liposomal gel formulation could be obtained by 
incorporating an appropriate amount of liposome contained 
in the gels, instead of increasing the concentration of F127. 
Liposome may not only provide the means for substantially 
increased lipophilic drug loading in gels, but it may also 
act as a reservoir for sustained or delayed drug release. 
Our results indicate that the mere presence of liposome 
comprising 0.21%–1.25% SPC may substitute for 3%–9% 
F127 concentration required for a gel-based delivery 
formulation and still maintain similar thermoreversibility 
and gel dissolution behavior. This has significant positive 
implications for the toxicity and economic issues related 
to using F127 in drug delivery. Adjusting the amount of 
liposome in gels is an easy, flexible means of adjusting the 
drug dose required to meet different therapeutic needs of 
individual patients. Secondly, in vitro cytotoxicity and drug 
uptake in KB cancer cells of the PTX-loaded liposomal 18% 
F127 system was much higher than that of conventional 
liposomes, implying that F127 could be used as an intracel-
lular penetration enhancer for liposomal drugs to improve 
their anticancer efficiency. At the same time, the cell cyto-
toxicity of corresponding blank liposomal 18% F127 gel 
was far less than that of the Cremophor EL vehicle and 
blank liposome. These results of our research collectively 
indicate that the utilization of liposomal thermoreversible 
gel as a non-Cremophor-based parenteral formulation for 
localized cancer therapy using hydrophobic anticancer 
agents such as PTX has a high potential for success.
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Figure 12 The cellular uptake intensity of fluorescent liposome in KB cells after 
4  hours  treatment.  Data  are  expressed  as  mean  ±  standard  deviation  (n  =  6). 
A) Treated with no formulation. B) Treated with NBD-labeled liposome. c) Treated 
with NBD-labeled liposomal 18% F127 gel.
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